RGEN

#1103
Repligen Corporation - Common Stock
122.5 1 USD
-0.18%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
121.95
123.80
Range Annuel
1.12
175.57
Changement quotidien
-0.18%
Changement Mensuel
+7.39%
Evolution sur 6 mois
-27.32%
Changement Annuel
-26.06%
Clôture Précédente
122.7 3
Open
122.8 2
Low
121.9 5
High
123.8 0
Volume
70
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 6.91 B
  • Employee 2 000
  • Founded 1981
  • CEO Tony J. Hunt
  • Website www.repligen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BS48J3
  • Industry Instruments et Fournitures Médicales
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
190.53
ratio cours/chiffre d'affaires
0.01

Repligen Corporation - Common Stock

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

Nouvelles